for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Suven Life Sciences Ltd.

SUVP.NS

Latest Trade

302.95INR

Change

1.25(+0.41%)

Volume

852,540

Today's Range

300.30

 - 

315.50

52 Week Range

182.70

 - 

334.70

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
301.70
Open
301.00
Volume
852,540
3M AVG Volume
7.62
Today's High
315.50
Today's Low
300.30
52 Week High
334.70
52 Week Low
182.70
Shares Out (MIL)
127.28
Market Cap (MIL)
38,401.13
Forward P/E
30.68
Dividend (Yield %)
--

Next Event

Q3 2020 Suven Life Sciences Ltd Earnings Release

Latest Developments

More

India's Suven Life Sciences Sept-Quarter Profit Rises

Suven Life Sciences Secures Product Patents In Israel,Japan, New Zealand & Sri Lanka

Suven Life Sciences Gets Product Patents In Eurasia, Europe, South Korea And Sri Lanka

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Suven Life Sciences Ltd.

Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3,4-dichlorobenzylamine. The Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.

Industry

Biotechnology & Drugs

Contact Info

SDE Serene Chambers 6th Floor

Road No. 5 Avenue 7, Banjara Hills

+91.40.23541142

http://www.suven.com/

Executive Leadership

Venkateswarlu Jasti

Executive Chairman of the Board, Chief Executive Officer

P. Subba E. Rao

Chief Financial Officer

K. Hanumantha Rao

Compliance Officer, Company Secretary

Sudha Rani Jasti

Wholetime Director

M. Gopalakrishna

Non-Executive Independent Director

Key Stats

1.75 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

5.4K

2018

6.3K

2019

6.6K

2020(E)

7.5K
EPS (INR)

2017

6.840

2018

9.700

2019

6.830

2020(E)

9.833
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
4.16
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
16.16
LT Debt To Equity (MRQ)
0.21
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Suven Life Sciences ‍Secures Product Patents In India And South Korea​

* PATENTS CORRESPONDING TO NEW CHEMICAL ENTITIES FOR TREATMENT OF DISORDERS RELATED TO NEURODEGENERATIVE DISEASES Source text: http://bit.ly/2sDvu6P Further company coverage:

BRIEF-Suven Life Sciences Secures Product Patents In Aripo, South Korea

* SUVEN LIFE SCIENCES - PATENTS FOR NCES FOR TREATING DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES; PATENTS VALID THROUGH 2033 AND 2034 Source text - http://bit.ly/2nnkGoi Further company coverage:

BRIEF-India's Suven Life Sciences Dec-Qtr Net Profit Rises

* DEC QUARTER NET PROFIT 346 MILLION RUPEES VERSUS PROFIT 242.7 MILLION RUPEES YEAR AGO

BRIEF-Suven Life Sciences Secures Product Patents In Canada, India

* SAYS PATENT CORRESPONDING TO NEW CHEMICAL ENTITIES (NCES) FOR TREATMENT OF DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES

BRIEF-Suven Life Sciences Gets Product Patents In India, U.S.

* SAYS CO SECURES PRODUCT PATENTS IN INDIA AND USA Source text - http://bit.ly/2AtbqHG Further company coverage:

BRIEF-India's Suven Life Sciences Secures Product Patents In Eurasia, Norway

* PATENTS CORRESPONDS TO NEW CHEMICAL ENTITIES (NCES) FOR TREATMENT OF DISORDERS ASSOCIATED WITH NEURODEGENERATIVE DISEASES Source text - http://bit.ly/2AUMl7N Further company coverage:

BRIEF-India's Suven Life Sciences gets product patents in Hong Kong,India & U.S.​

* Patents corresponds to new chemical entities for treatment of disorders associated with neurodegenerative diseases

BRIEF-India's Suven Life Sciences gets product patent in Singapore

* Gets product patent from Singapore related to new chemical entities for treating disorders associated with neurodegenerative diseases Source text - http://bit.ly/2ghXZxC Further company coverage:

BRIEF-Suven Life Sciences gets product patent in New Zealand​

* Product patent corresponds to New Chemical Entities (NCEs) for treatment of disorders associated with neurodegenerative diseases

BRIEF-Suven Life Sciences secures product patents in India, Japan

* Says Suven Life Sciences secures product patents in India and Japan

BRIEF-Suven Life Sciences gets product patent in Japan​

* Patent for new chemical entities for the treatment of disorders associated with neurodegenerative diseases

BRIEF-Suven Life Sciences secures process patents in Europe, Japan and New Zealand

* Patents for new chemical entities for treatment of disorders associated with neurodegenerative diseases Source text: (http://bit.ly/2vKB7xV) Further company coverage:

BRIEF-India's Suven Life Sciences June-qtr profit falls

* June quarter net profit 295.7 million rupees versus 325.8 million rupees year ago

BRIEF-Suven Life Sciences secures product patent in Australia

* Says Suven Life Sciences secures a product patent in Australia

BRIEF-Suven Life Sciences secures product patent in Australia and the U.S.

* Suven Life Sciences secures a product patent in Australia and USA

BRIEF-Suven Life Sciences secures product patent in New Zealand

* Says Suven Life Sciences secures a product patent in New Zealand

BRIEF-Suven Life Sciences Dec qtr profit rises

* Suven Life Sciences Ltd - dec quarter net profit 242.7 million rupees versus profit 170.6 million rupees year ago

BRIEF-Suven Life Sciences secures product patent in U.S.

* Says Suven Life Sciences secures a product patent in USA Source text: http://bit.ly/2jtMu5r Further company coverage:

BRIEF-Suven Life Sciences gets 2 product patents in China, Mexico

* Patents are valid through 2032 and 2031 Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up